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patients presented an overall clinical improvement of ≥ 20%, ≥ 50% and ≥ 80%. These 
improvements were associated with a reduction of steroid use (75% of patients 
on steroids at belimumab-initiation decreased mean dose from 14.8 to 6.8mg/day; 
p< 0.001) and HRU between the pre/post index periods: emergency-room visits 1.65 
to 0.41; p= 0.001; unscheduled visits to treating-physician 1.02 to 0.03; p< 0.001, 
visits to other specialists (1.64 to 1.06; p= 0.017) and antibody tests (7.78 to 7.53; 
p= 0.47). An increase in HRU was observed for hematological and renal tests (3.14 to 
3.52; p= 0.045) and (5.95 to 6.59; p= 0.024), respectively. Working patients (39%) also 
showed a reduction in the LA days between the pre/post index periods (25.6 to 5.7 
days; p= 0.025). ConClusions: Belimumab treatment yielded improved clinical 
outcomes and a reduction in HRU directly related with SLE management, as corti-
coid use. Mean number of LA days also showed a substantial reduction, especially 
important in SLE, mostly affecting young patients.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes & Patient 
Preference Studies
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IMPaCT Of PaTIENT PROgRaMS ON aDhERENCE IN INflaMMaTION aND 
IMMuNOlOgY: a glObal SYSTEMaTIC REvIEw aND METa-aNalYSIS Of 
PublIShED EvIDENCE
Burudpakdee C.1, Khan Z.M.2, Gala S.1, Nanavaty M.1, Kaura S.2
1MKTXS, Raritan, NJ, USA, 2Celgene Corporation, Summit, NJ, USA
objeCtives: Patient adherence is important for successful treatment in chronic 
conditions, including inflammation and immunology (I&I) diseases, to improve 
patient outcomes. Programs and interventions that aim at improving medica-
tion adherence play an essential role in optimizing care. This review and meta-
analysis assessed the effectiveness of different types of adherence programs in 
I&I. Methods: A global systematic literature search was conducted and studies 
were identified from PubMed, conference proceedings, and grey literature. Selection 
criteria included studies of patient programs in I&I diseases published in English 
language between January 2008 and September 2013 that reported % of adherent 
patients. A meta-analysis was performed using a random effects model. Weights, 
odds ratios, 95% CI, and forest plots were developed for behavioral, informational, 
and combination interventions. Results: Of 29 studies screened, a total of 13 stud-
ies were eligible for inclusion in the meta-analysis. Seven studies were in patients 
with osteoporosis, 4 in ulcerative colitis, 1 in childhood-onset systemic lupus ery-
thematosus, and 1 in rheumatoid arthritis / psoriasis. Overall, patient programs 
increased adherence (OR = 2.48, 95% CI = 1.68 - 3.64, P < 0.00001) as compared 
to standard of care or no intervention. Combination interventions that used both 
informational and behavioral strategies were superior in increasing adherence (OR 
= 3.68, 95% CI = 2.20 - 6.16, P < 0.00001) compared to interventions using solely a 
behavioral strategy (OR = 1.85, 95% CI = 1.00 - 3.45, P = 0.05) or only an informational 
strategy (OR = 2.16, 95% CI = 1.36 - 3.44, P = 0.001). ConClusions: Patient programs 
and interventions can significantly improve adherence in I&I diseases as compared 
to standard of care or no intervention. Programs employing a multimodal approach 
are more effective in improving adherence than either informational or behavioral 
strategies alone. This in turn may improve patient outcomes.
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aDhERENCE TO aNTICOagulaNT ThERaPY IN ChIlDREN hOSPITalIzED fOR 
PulMONaRY EMbOlISM aND DEEP vEIN ThROMbOSIS
Singh R.R.1, Gupte K.P.1, Wilson J.P.1, Moffett B.S.2
1The University of Texas at Austin, Austin, TX, USA, 2Baylor College of Medicine/Texas Children’s 
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objeCtives: The American College of Chest Physicians Guideline recommends anti-
coagulant therapy for at least three months in children with venous thromboembo-
lism. The objectives of the study were to evaluate the medication utilization patterns, 
and the predictors of adherence to anticoagulant therapy in the pediatric popula-
tion. Methods: Texas Medicaid medical and prescription claims from June 01, 
2007 to September 31, 2012 were extracted for children (< 18 years) hospitalized 
for Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT). The index date was 
defined as the date of the first prescription of an anticoagulant warfarin (oral) 
and/or enoxaparin (injectable) given within 14 days after discharge from hospi-
talization. Patients hospitalized for atrial fibrillation, air/fat embolism, bleeding/
coagulation disorder within 90 days of discharge were excluded. Proportion of 
days covered (PDC≥ 80% vs. < 80%) was used to assess adherence to anticoagulants 
while controlling for demographics, cause of hospitalization, history of NSAID use, 
anticoagulant use, malignancy, drug type, and Charlson comorbidity index (CCI). A 
multivariate logistic regression analysis was used. Results: The patients (n= 57) 
had a mean (±SD) age of 14.1 (±4.9) years, were primarily female (54.4%), African 
American (61.4%), enoxaparin users (54.4%), and had a mean (±SD) CCI of 19.7 (±39.4). 
The mean (±SD) adherence rates for warfarin and enoxaparin were 85.6% (±22.3%) 
and 78.2% (±22.7%), respectively. 66.7% were adherent (PDC≥ 80%) to anticoagulant 
therapy. The median (Mean±SD) persistence with anticoagulant therapy was 84.6 
(71.9±33.3) days. Logistic regression showed that increasing age was significantly 
associated with adherence to anticoagulant therapy (Odds Ratio= 1.3, p= 0.0158), 
after controlling for covariates. ConClusions: Nearly one third of the pediatric 
patients on anticoagulant therapy after discharge from hospitalization with PE or 
DVT were non-adherent. Further research is needed to underline the factors respon-
sible for non-adherence in pediatric patients.
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NEw ObSERvER-REPORTED OuTCOMES TO MEaSuRE TREaTMENT 
SaTISfaCTION, COMPlIaNCE, PalaTabIlITY, aND gI SYMPTOMS fOR 
PaTIENTS NEEDINg IRON-ChElaTION ThERaPY
Lasch K.1, Horodniceanu E.G.2, Carter J.A.2, Dhatt H.2, Bal V.3, Côté I.3, Constantinovici N.4, 
Herranz R.M.4, Malet I.4
480 mg respectively) before rotation the number of milligrams of each opioid was 
calculated based on equianalgesic tables using only direct medical costs, further 
a deterministic sensitivity analysis was performed. Results: The results dem-
onstrate that methadone (Amidone ®) generates average savings per patient of 
$ 84.37 to $ 5,817.00 compared to oxycodone, buprenorphine (PT), fentanyl (PT) and 
hydromorphone in the three subgroups analyzed, the sensitivity analysis shows 
that methadone remains a cost-saving option. ConClusions: Using Methadone 
(Amidone ®) is a cost-saving option for patients with acute and chronic severe pain 
secondary to cancer in Mexico, from the institutional point of view.
PSY71
REal-wORlD COST-uTIlITY EvaluaTION Of MulTIPlE MYElOMa 
TREaTMENTS IN STEM CEll TRaNSPlaNTED PaTIENTS
Gilabert Sotoca M., Schoenenberger Arnaiz J.A., Pons Llobet N., Martinez Sogues M., 
Mangues Bafalluy I., Martinez Castro B.
Hospital Universitari Arnau de Vilanova, Lleida, Spain
objeCtives: Multiple myeloma (MM) is an incurable disease with an incidence 
of 4-7 new cases by 100.000 people. In the setting of the study, 28% of the yearly 
25 news cases of MM are candidates to autologous stem cell transplant (ASCT). 
Because of the lack of real-world economic studies, authors sought to describe 
the cost per quality-adjusted-life-year (QALY) of the MM treatment in a group of 
transplanted patients. Methods: An observational retrospective study was per-
formed and included detailed clinical data from a transplanted cohort of patients 
with MM. All patients received bortezomib based treatments. Costs were evaluated 
from the payer’s perspective and included total drug costs and hospital admission 
costs. QALYs values were obtained from the CEA Registry of Tufts University. Four 
health states were considered: complete response (CR), partial response, stability 
and progressive disease. Time between state transitions was used to calculate QALYs 
for each patient. Results: The study included 17 patients with a mean age of 61,2 
years; 12 of them (Group 1) were followed during 2,77±0,24 years and 5 (Group 2) dur-
ing 1,6±0,19 years. Global complete response rate one year after ASCT was 8/17 (47%) 
and dropped to 5/12 (41,6%) at two years. For the whole cohort the median of QALY’s 
cost was 56.198€ (IQ range 36.391-70.339). For patients with CR one year after ASCT, 
the median of QALY’s cost was 46.358€ (IQ range 36.299-67.537). For all other patients 
the median of QALY’s cost was 56.676€ (IQ range 39.114-73.613). For Group 1 patients, 
the median of QALY’s cost was 51.278€ (IQ range 36.345-73.613). ConClusions: 
These results reveal that the actual costs of MM treatment using protocols that 
include bortezomib are above the 30.000-50.000€ threshold generally admitted in 
cost-effectiveness studies.
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ORPhaN DRug PRICINg IN fRaNCE: INfluENCE Of MaIN faCTORS
GRAND H.1, Samson A.L.2, Aulois-Griot M.1
1Université Bordeaux, Bordeaux, France, 2Université Paris Dauphine, Paris, France
objeCtives: Orphan drugs (OD) require considerable expenditures, which causes 
difficulties in their market access. For several years, the price of these new therapies 
has often been criticized and considered as too high. However few studies about 
OD pricing mechanisms are available. The aim of the paper is to highlight the main 
factors that influence OD pricing in France. Methods: We collected public prices 
of 37 products designated as OD and approved by the European Medicines Agency 
until January 2014. Given that an OD can have several indications, our database 
contains 49 observations. For each observation, we calculated the ex-factory price 
without tax (defined per daily dose) defined by summary products characteristics. 
We also collected different characteristics of these products: improvement in actual 
clinical benefit (IACB), actual clinical benefit (ACB), number of OD indications, 
number of comparators drugs, number of competing orphan drugs, therapeutic 
use, target population, inclusion on the list of medicines reimbursed by National 
Health Insurance. Ordinary least squares are used to analyse the determinants of 
OD prices. Results: The distribution of OD prices is very heterogeneous, with a 
minimum of 2.34 euros and a maximum of 2882.08 euros. The average (SD) price 
is 380.675 euros (687.414). Our main results are that OD prices are significantly 
lower for OD that do not improve actual clinical benefit (-136%, p= 0.024), for OD 
with only one orphan indication (-80%, p= 0.047), and for OD with a high target 
population (-251%, p= 0.000). ConClusions: There is a need to understand OD 
pricing mechanisms. Our study shows that innovation and research efforts are 
encouraged by pricing policy.
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EvaluaTION Of uSE Of bElIMuMab IN ClINICal PRaCTICE SETTINgS 
(ObSERvE STuDY) IN SPaIN: hEalTh RESOuRCE uTIlIzaTION aND labOuR 
abSENTEEISM
Cortés J.1, Andreu J.L.2, Calvo J.3, García-Aparicio A.M.4, Coronell C.G.5, Díaz-Cerezo S.5
1Hospital Vall d´Hebrón, Barcelona, Spain, 2Hospital Puerta de Hierro, Majadahonda (Madrid), 
Spain, 3Hospital de Sierrallana, Torrelavega, Spain, 4Hospital VIrgen de la Salud, Toledo, Spain, 
5GSK España, Tres Cantos, Spain
objeCtives: To analyze the health resource utilization (HRU) and labour absentee-
ism (LA) in Systemic Lupus Erythematosus (SLE) patients treated with belimumab 
in the Spanish clinical setting. Methods: OBSERVE is a multicenter retrospective 
medical chart-review study. Twenty-five rheumatologists from Spanish hospitals 
with > 10 SLE patients annually and > 5-years of practice experience identified adult 
SLE patients who had received 6-months of belimumab treatment. In the 6-months 
pre- and 6-months post-index periods physicians assessed: demographics, comor-
bidities, SLE disease characteristics, treatment clinical outcomes, HRU and LA data. 
Index-date is the date of the first infusion. OBSERVE primary endpoint was overall 
clinical response per physician judgment. Statistical analyses included appropri-
ate tests for paired-samples (parametric/ non-parametric). Two-way P-values 0.05 
were considered statistically significant. Results: A total of 64 patients were eli-
gible for analysis: mean age 42.7±12 years; female 89%; hypocomplementemia 70% 
and high anti-dsDNA 69%. After receiving 6-months therapy, 72%, 52% & 27% of 
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outcomes and greater indirect costs. The distribution of BMI is similar to the 5 E.U. 
Finding suggest the need for additional weight-loss options.
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ThE MulTICENTRIC CaSTlEMaN’S DISEaSE (MCD) -SYMPTOM SCalE 
(MCD-SS): DEvElOPMENT aND valIDaTION Of a PaTIENT-REPORTED 
OuTCOME (PRO) MEaSuRE fOR aN ulTRa-ORPhaN DISEaSE
Casper C.1, Van Agthoven M.2, Rothman M.3, Fleming S.4, Ho K.F.4, Qi M.4, Vermeulen J.5,  
Cavet J.6
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Janssen-Cilag BV, Tilburg, The The 
Netherlands, 3Janssen Global Services, LLC, Spring House, PA, USA, 4Janssen R&D, US, Spring 
House, PA, USA, 5Janssen, Leiden, The Netherlands, 6Christie Hospital, Manchester, UK
objeCtives: MCD, an ultra-orphan lymphoproliferative disorder with heteroge-
neous symptomology, including fatigue, malaise, sweats, and nodal/extranodal 
masses, is driven by dysregulated interleukin-6 signaling. Siltuximab, an anti-
interleukin-6 antibody, is approved in the US and EU for treatment of human immu-
nodeficiency virus (HIV) - and human herpes virus-8 (HHV-8) -negative adult MCD 
patients. This study aimed to fill an unmet need for a validated PRO tool to quantify 
MCD symptoms and responses to therapy. Methods: Using FDA guidance, an MCD 
symptom scale (MCD-SS) was developed by collecting and evaluating symptoms 
in 12 patients from 2 US centers, with further validation using additional patients 
from 1 US center. Item performance, scale structure and scoring, reliability, validity, 
responsiveness, and clinically meaningful change were evaluated in a randomized, 
placebo-controlled, double-blind study of siltuximab (N= 79) in HIV-, HHV-8-negative 
MCD patients (Wong Blood 2013:122 (21)). Results: Patient-reported MCD symp-
toms were: cough, dizziness, drowsiness, dry mouth, fever, headaches, hot flashes, 
itching, skin lesions, loss of appetite, nausea, numbness/tingling, pain, rash, short-
ness of breath, sweating, swollen lymph nodes, swelling/edema, tiredness/fatigue, 
vomiting, weakness, weight gain, and weight loss. Following exploratory factor 
analysis, 3 domains were created: fatigue, rash/itching, and sweats (total score also 
calculated). The final MCD-SS comprised 16 questions with 6 response options: “did 
not experience,” “very mild,” “mild,” “moderate,” “severe,” and “very severe” (score, 
0-5). Subjects reported a mean (SD) and median (range) of 9.2 (3.76) and 9.5 (1-16) 
symptoms, respectively. Test-retest reliability was acceptable (r> 0.70) for fatigue, 
sweats, and the total score but lower for rash/itching (r= 0.65). Internal consistency 
exceeded 0.70 for all. Lower ECOG scores were associated with lower MCD-SS scores. 
MCD-SS total scores were moderately correlated (r= 0.48) with baseline clinician-
reported signs and symptoms. ConClusions: This is the first known attempt to 
develop a PRO instrument for MCD. These data support further use of the MCD-SS 
in the target population.
PSY80
“I DON’T KNOw hOw IT haPPENED OR whEN EvERYThINg ChaNgED. 
IT’S lIKE I blINKED aND all Of a SuDDEN, I DIDN’T RECOgNISE MY OwN 
bODY”: uSINg QualITaTIvE INSIghTS TO DEvElOP a CONCEPTual MODEl 
TO uNDERSTaND ThE lIvED ExPERIENCE Of PaTIENTS wITh SYSTEMIC 
SClEROSIS
Willgoss T.G.1, Humphrey L.1, Blankenburg M.2
1Abacus International, Manchester, UK, 2Bayer HealthCare Pharmaceuticals, Berlin, Germany
objeCtives: Systemic sclerosis (SSc) is a rare, multisystem chronic disease char-
acterised by fibrotic changes affecting all or some bodily organs. SSc is associated 
with high morbidity and a significant effect on patients’ health-related quality 
of life. Qualitative insights can provide rich context to the patients’ experience 
of a disease. Conceptual models based on qualitative data are a valuable way to 
“explain, with graphically or narrative form, the main things to be studied - the key 
factors, concepts and variables – and the presumed relationships between them”. 
Despite the existence of SSc-specific measures, no conceptual model of SSc exists. 
This research aimed to develop a qualitatively-derived, patient-centred, conceptual 
model of SSc. Methods: To identify patient-reported SSc symptoms and impacts, 
we reviewed qualitative literature (published since 2000 to limit the search) in 
which experiences of living/coping with SSc are described. We also reviewed social 
media blogs/forums to identify additional concepts and provide supporting quotes. 
Concepts were identified by independent researchers who collaboratively developed 
the model. Results: Twelve qualitative studies and 150 social media posts were 
reviewed. The review identified 56 symptom concepts, which were categorised into 
13 domains (peripheral, cognitive, pain, neurological, cardiorespiratory, ophthalmo-
logical, gastrointestinal, fatigue, nasopharyngeal, weight, oesophageal, dizziness, 
nausea) and 48 impact concepts, which were categorised into 8 domains (daily living, 
diet, social, clothing, work, physical and psychological functioning). Of note, nausea 
and dizziness were identified only through the social media review. ConClusions: 
A conceptual model for SSc was developed based on qualitative insights. The model 
depicts the diverse range of symptoms and impacts experienced by patients. By 
incorporating a social media review, relevant symptoms, which would not have 
otherwise been identified, were found and included in the model. This research is 
an important first step in identifying the most relevant and conceptually compre-
hensive clinical outcomes assessments for clinical research/practice.
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PREvalENCE Of NEuROPaThIC PaIN aND ITS DISEaSE buRDEN IN KOREa 
PaTIENTS wITh luMbaR SPINE SuRgERY
Cho Y.E.1, Moon S.H.2, Whang C.J.3, Kim H.J.4
1Gangnam Severance Spine Hospital, Yonsei University College of Medicine, Seoul, South 
Korea, 2Department of Orthopedics, College of Medicine, Yonsei University, Seoul, South Korea, 
3Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea, 4Pfizer 
Pharmaceuticals Korea Limited, Seoul, South Korea
objeCtives: The objectives of this study were to investigate the prevalence of 
Neuropathic Pain (NP) and newly occurred (de novo) NP postoperatively. This study 
also aimed to identify the disease burden (pain severity and quality of life (QoL)) 
of NP. Methods: This study was a nationwide, multi-centered, prospective, and 
1Pharmerit International, Cambridge, MA, USA, 2Pharmerit International, Bethesda, MD, USA, 
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Novartis Pharma AG, Basel, 
Switzerland
objeCtives: Adherence to iron chelation therapy (ICT) is essential for patients with 
transfusion-dependent anemia (TDA) (e. g., sickle cell disease [SCD] and thalas-
semia) to increase survival and minimize disease-related sequellae. Adherence has 
been noted as especially problematic for children and adolescents. In order to meas-
ure compliance and treatment satisfaction in young children, the Satisfaction with 
Iron Chelation Therapy (SICT) instrument (initially developed for use by adults and 
adolescents) was modified to be an observer-reported outcome (ObsRO) measure to 
be administered electronically to caregivers. In addition, three other ObsROs were 
developed measuring compliance, palatability, and gastrointestinal (GI) symptoms 
related to treatment benefit of a new ICT formulation. Methods: Subjects included 
10 caregivers of children with TDA. Informed consent was obtained. Two sets of 
face-to-face cognitive interviews were conducted iteratively with modification to 
items and further debriefing of modifications. Interviews began with an open-ended 
question to elicit caregivers’ and their reports of their child’s experiences with 
ICT. Interviews were audio recorded and transcribed. Data were analyzed using 
ATLAS. ti software. Results: Three interviewers conducted 10 caregiver inter-
views in 6 US cities. Caregivers were 90% female aged 35-65 (mean= 48). Children 
of caregivers included those with SCD (80%) and thalassemia (20%) and were 60% 
female, aged 2-17 (mean= 9). Responses to the open-ended question confirmed 
several concepts in the modified SICT and the need for new items. The result-
ant questionnaires included the modified SICT (17 items), Compliance (2 items), 
Palatability (4 items), and GI Symptom Diary (6 items). Changes were made to each 
to ensure comprehension, relevance, lack of redundancy, and appropriate response 
options. ConClusions: Evidence supports the content validity of the modified 
SICT, Compliance, Palatability, and GI Symptom Diary questionnaires. Use in clinical 
research awaits tests of validity, reliability, and responsiveness.
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IMPaCT Of PulMONaRY ExaCERbaTIONS ON EQ-5D MEaSuRES IN PaTIENTS 
wITh CYSTIC fIbROSIS
Solem C.T.1, Vera-Llonch M.2, Liu S.1, Botteman M.1, Lin F.J.1, Castiglione B.2
1Pharmerit International, Bethesda, MD, USA, 2Vertex Pharmaceuticals, Boston, MA, USA
objeCtives: Pulmonary exacerbations (PEs) in patients with cystic fibrosis (CF) 
have been reported to impact health-related quality of life. This analysis exam-
ined the impact of PEs on EQ-5D measures in patients with CF using trial-based 
data. Methods: In a 48-week randomized, placebo-controlled study of ivacaftor 
in patients ≥ 12 years with CF and a G551D-CFTRmutation, the EQ-5D questionnaire, 
including visual analog scale (EQ VAS), was administered at baseline, 15 days, 8 
weeks, and every 8 weeks thereafter. UK preference weights were employed to 
derive the EQ-5D index. PE was defined as a change in antibiotic therapy for ≥ 4 of 
12 signs or predefined symptoms. EQ-5D measures collected in the 8-week pre- and 
post- exacerbation periods were examined after pooling observations across study 
treatments and visits. Results: A total of 146 PEs were experienced by 72 (44.7% of 
total 161) patients, including 52 (35.6%) PEs that required hospitalization. Mean (±SD) 
duration was 30.0±22.2 days for PEs requiring hospitalization (n= 48) and 20.6±11.6 
days for those not requiring hospitalization (n= 89) (9 PEs had missing end dates). 
For PEs requiring hospitalization, mean (±SD) EQ-5D index/VAS scores within 1-8 
weeks before PE start were 0.91 (±0.13)/75.5 (±14.2), respectively. The lowest aver-
age EQ-5D index/VAS scores were reached within 1 week of PE start; mean scores 
within 1 week were 0.76±0.33 (p= 0.044 vs. 1-8 weeks prior to PE) /63.7±24.1 (p= 0.039). 
Corresponding values for PEs not requiring hospitalization were 0.89±0.16/73.4±16.1 
within 1-8 weeks before PE start, and 0.90±0.13 (p= 0.777) /68.4±17.4 (p= 0.124) within 
1 week of PE start. ConClusions: In a clinical study of patients with CF (≥ 12 years 
of age and a G551D-CFTR mutation), the PEs were associated with lower EQ-5D and 
VAS scores, primarily among those requiring hospitalization. Reducing PEs requir-
ing hospitalization is likely to improve health-related quality of life among these 
patients.
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IS ObESITY a PROblEM IN bRazIl?
Richard L.1, Gupta S.2, Pomerantz D.2, Forsythe A.3
1Eisai Europe Ltd, Hatfield, UK, 2Kantar Health, Princeton, NJ, USA, 3Eisai Inc., Woodcliff Lake, 
NJ, USA
objeCtives: This study investigated the effect of BMI on quality of life, pro-
ductivity, activity impairment, health care resource-utilisation, and associated 
costs. Methods: Results were from the 2011-2012 Brazil National Health and 
Wellness Survey (N= 24,000), a nationally representative, online survey of respond-
ents aged≥ 18 years. Analysis focused on normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obese class (OC) I (BMI≥ 30 & < 35 kg/m2), OC II 
(BMI≥ 35 & < 40 kg/m2), and OC III (BMI≥ 40 kg/m2) respondents. Outcomes included 
quality of life (SF-36v2), health utilities (SF-6D), productivity loss (Work Productivity 
and Activity Impairment questionnaire) and resource utilisation (type/number of 
visits) in the past six months. Direct and indirect costs were estimated from public 
sources. Generalised linear models predicted outcomes as a function of BMI cat-
egory, adjusting for covariates (e. g., age, gender, comorbidities). Results: Among 
22,871 respondents, 46.4% were normal weight, 34.9% were overweight, 12.9% were 
OC I, 3.7% were OC II, and 2.0% were OC III. Adjusting for covariates, mental, physi-
cal component summary (normal weight: 51.8; overweight: 51.4; OC I: 50.3; OC II: 
48.5; OC III: 46.0), and health utilities (normal weight: 0.73; overweight: 0.72; OC I: 
0.71; OC II: 0.70; OC III: 0.67) decreased as BMI increased (OCs vs. normal, p< 0.05). 
Amongst the employed (66.1%), impairment while working (normal weight: 15.5%; 
overweight: 15.6%; OC I: 16.9%; OC II: 18.2%; OC III: 22.4%, OCs vs. normal, p< 0.05) 
increased as BMI increased. Normal weight (vs. OCs, p≤ 0.05) had lower activity 
impairment, fewer provider visits, and lower indirect costs (normal weight: R$333; 
overweight: R$338; OC I: R$385; OC II: R$395; OC III: R$458). ConClusions: Over 
50% of Brazilians are overweight or obese. Increase in BMI is associated with poorer 
